The UK and US have signed a significant bilateral deal that will maintain zero import taxes on UK medicine shipments being sold in the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has committed to boost expenditure on pharmaceuticals through the National Health Service (NHS). This pledge ensures that tariffs on these crucial goods will be held at nothing for a timeframe of 36 months.
This agreement is in response to previous threats to significantly raise tariffs on patented drug products, with figures discussed as high as one hundred percent.
"This deal with the UK reinforces the international landscape for cutting-edge drugs and introduces long-overdue equity to transatlantic drug exports," an announcement noted.
Trade Importance
Pharmaceuticals represent one of the the United Kingdom's most significant goods shipped to the America, which is clearly the primary destination for major companies like GSK and AstraZeneca.
Trade data reveal that in the year prior to September, the UK shipped pharmaceutical products totaling over eleven billion pounds to the US. This amount represented a significant portion of all goods exports in that timeframe.
"This deal protects employment, boosts capital expenditure and facilitates the UK to establish itself as a worldwide center for medical research," the Business and Trade Secretary stated.
Detailed NHS Changes
The agreement includes several key changes from the British government:
- Price Threshold Increase: The UK will raise the price threshold at which it judges new medicines to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a aim to double total health service expenditure on drugs from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The percentage manufacturers must pay back to the NHS to control costs will be capped at fifteen percent. Last year, repayments were more than twenty percent.
Broader Context
The deal takes place against a protracted dispute between the drug companies and the ministers over spending levels and approval rates.
These tensions were intensified by assertions that American patients were paying a premium for the equivalent treatments than consumers in the UK and Europe.
Recently, several large drug company projects in the UK have been paused or scrapped, while major funding commitments have been directed toward projects in the United States.
A senior figure acknowledged that the NHS had to invest a greater share on treatments, noting that its budget allocation on drugs had declined as a proportion of its resources over the previous ten-year period.
